GHRS

About GH Research PLC Ordinary Shares (GHRS) Stock

GH Research PLC Ordinary Shares (GHRS) closed the 2026-09-15 session at $27.55, down 1.22% versus the previous close (-0.34). The stock opened at $27.63 and traded between $26.52 and $27.83 during that session. Session trading volume was 140K shares. The volume-weighted average price (VWAP) is $27.36.

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

GH Research PLC Ordinary Shares has a market capitalization of $1.89 billion. GHRS is listed on the XNAS exchange. The company employs approximately 73 people. The recorded listing date is 2021-06-25.

On this page you can find market GHRS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.